Clinical Trial Update: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) [Phase 1, Phase 2]

View source ↗

Summary

This update covers a Phase 1/2 trial of pembrolizumab, alone or with investigational agents, in Stage III melanoma patients eligible for neoadjuvant therapy (MK…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED